Global Diabetic Nephropathy 麻豆原创 Research Report 2024

Publication ID:

PB502241909

Publication Date:

March 5, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market.
The global Diabetic Nephropathy market was valued at US$ 2446.7 million in 2023 and is anticipated to reach US$ 3498 million by 2030, witnessing a CAGR of 4.8% during the forecast period 2024-2030.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents鈥� wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
This report aims to provide a comprehensive presentation of the global market for Diabetic Nephropathy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetic Nephropathy.
Report Scope
The Diabetic Nephropathy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Diabetic Nephropathy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diabetic Nephropathy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Novartis
Merck
Pfizer
Abbott Laboratories
Sanofi
Eli Lilly
AbbVie
Reata Pharmaceuticals
Bayer
Mitsubishi Tanabe Pharma
Segment by Type
ACE Inhibitors
ARBs
Diuretics
Calcium Channel Blockers(CCBs)
Renin Inhibitors
Connective Tissue Growth Factor (CTGF) Inhibitors
Antioxidant Inflammation Modulators(AIMs)
Monocyte Chemoattractant Protein (MCP)Inhibitors
Endothelin-A Receptor(ETAR)Antagonist
G Protein-Coupled Receptors (GPCRs)
Segment by Application
Hospitals
Cancer Research Institutes
Diagnostic Labs
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Diabetic Nephropathy companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Diabetic Nephropathy 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 ACE Inhibitors
1.2.3 ARBs
1.2.4 Diuretics
1.2.5 Calcium Channel Blockers(CCBs)
1.2.6 Renin Inhibitors
1.2.7 Connective Tissue Growth Factor (CTGF) Inhibitors
1.2.8 Antioxidant Inflammation Modulators(AIMs)
1.2.9 Monocyte Chemoattractant Protein (MCP)Inhibitors
1.2.10 Endothelin-A Receptor(ETAR)Antagonist
1.2.11 G Protein-Coupled Receptors (GPCRs)
1.3 麻豆原创 by Application
1.3.1 Global Diabetic Nephropathy 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Cancer Research Institutes
1.3.4 Diagnostic Labs
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Nephropathy 麻豆原创 Perspective (2019-2030)
2.2 Diabetic Nephropathy Growth Trends by Region
2.2.1 Global Diabetic Nephropathy 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Diabetic Nephropathy Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Diabetic Nephropathy Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Diabetic Nephropathy 麻豆原创 Dynamics
2.3.1 Diabetic Nephropathy Industry Trends
2.3.2 Diabetic Nephropathy 麻豆原创 Drivers
2.3.3 Diabetic Nephropathy 麻豆原创 Challenges
2.3.4 Diabetic Nephropathy 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Nephropathy Players by Revenue
3.1.1 Global Top Diabetic Nephropathy Players by Revenue (2019-2024)
3.1.2 Global Diabetic Nephropathy Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Diabetic Nephropathy 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Diabetic Nephropathy Revenue
3.4 Global Diabetic Nephropathy 麻豆原创 Concentration Ratio
3.4.1 Global Diabetic Nephropathy 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Nephropathy Revenue in 2023
3.5 Diabetic Nephropathy Key Players Head office and Area Served
3.6 Key Players Diabetic Nephropathy Product Solution and Service
3.7 Date of Enter into Diabetic Nephropathy 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Diabetic Nephropathy Breakdown Data by Type
4.1 Global Diabetic Nephropathy Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Diabetic Nephropathy Forecasted 麻豆原创 Size by Type (2025-2030)
5 Diabetic Nephropathy Breakdown Data by Application
5.1 Global Diabetic Nephropathy Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Diabetic Nephropathy Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Diabetic Nephropathy 麻豆原创 Size (2019-2030)
6.2 North America Diabetic Nephropathy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Diabetic Nephropathy 麻豆原创 Size by Country (2019-2024)
6.4 North America Diabetic Nephropathy 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Diabetic Nephropathy 麻豆原创 Size (2019-2030)
7.2 Europe Diabetic Nephropathy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Diabetic Nephropathy 麻豆原创 Size by Country (2019-2024)
7.4 Europe Diabetic Nephropathy 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Diabetic Nephropathy 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Diabetic Nephropathy 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Diabetic Nephropathy 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Diabetic Nephropathy 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Diabetic Nephropathy 麻豆原创 Size (2019-2030)
9.2 Latin America Diabetic Nephropathy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Diabetic Nephropathy 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Diabetic Nephropathy 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Diabetic Nephropathy 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Diabetic Nephropathy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Diabetic Nephropathy 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Diabetic Nephropathy 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Diabetic Nephropathy Introduction
11.1.4 Novartis Revenue in Diabetic Nephropathy Business (2019-2024)
11.1.5 Novartis Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Diabetic Nephropathy Introduction
11.2.4 Merck Revenue in Diabetic Nephropathy Business (2019-2024)
11.2.5 Merck Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Diabetic Nephropathy Introduction
11.3.4 Pfizer Revenue in Diabetic Nephropathy Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Company Detail
11.4.2 Abbott Laboratories Business Overview
11.4.3 Abbott Laboratories Diabetic Nephropathy Introduction
11.4.4 Abbott Laboratories Revenue in Diabetic Nephropathy Business (2019-2024)
11.4.5 Abbott Laboratories Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Diabetic Nephropathy Introduction
11.5.4 Sanofi Revenue in Diabetic Nephropathy Business (2019-2024)
11.5.5 Sanofi Recent Development
11.6 Eli Lilly
11.6.1 Eli Lilly Company Detail
11.6.2 Eli Lilly Business Overview
11.6.3 Eli Lilly Diabetic Nephropathy Introduction
11.6.4 Eli Lilly Revenue in Diabetic Nephropathy Business (2019-2024)
11.6.5 Eli Lilly Recent Development
11.7 AbbVie
11.7.1 AbbVie Company Detail
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Diabetic Nephropathy Introduction
11.7.4 AbbVie Revenue in Diabetic Nephropathy Business (2019-2024)
11.7.5 AbbVie Recent Development
11.8 Reata Pharmaceuticals
11.8.1 Reata Pharmaceuticals Company Detail
11.8.2 Reata Pharmaceuticals Business Overview
11.8.3 Reata Pharmaceuticals Diabetic Nephropathy Introduction
11.8.4 Reata Pharmaceuticals Revenue in Diabetic Nephropathy Business (2019-2024)
11.8.5 Reata Pharmaceuticals Recent Development
11.9 Bayer
11.9.1 Bayer Company Detail
11.9.2 Bayer Business Overview
11.9.3 Bayer Diabetic Nephropathy Introduction
11.9.4 Bayer Revenue in Diabetic Nephropathy Business (2019-2024)
11.9.5 Bayer Recent Development
11.10 Mitsubishi Tanabe Pharma
11.10.1 Mitsubishi Tanabe Pharma Company Detail
11.10.2 Mitsubishi Tanabe Pharma Business Overview
11.10.3 Mitsubishi Tanabe Pharma Diabetic Nephropathy Introduction
11.10.4 Mitsubishi Tanabe Pharma Revenue in Diabetic Nephropathy Business (2019-2024)
11.10.5 Mitsubishi Tanabe Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Novartis
Merck
Pfizer
Abbott Laboratories
Sanofi
Eli Lilly
AbbVie
Reata Pharmaceuticals
Bayer
Mitsubishi Tanabe Pharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.